Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 19/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 16/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193391 | 0.92 | ADRA1A (0.37) | ADRA1AADRA1BADRA1DCYP3A4CYP2C9 | |
| SCHEMBL6193244 | 0.85 | TSHR (0.39) | ADRA1ADRD2 | |
| SCHEMBL6191936 | 0.83 | MEN1 (0.37) | ADRA1AADRA1BADRA1DDRD2 | |
| SCHEMBL6192784 | 0.82 | HTR1A (0.39) | ADRA1ADRD2 | |
| SCHEMBL7052096 | 0.82 | DRD3 (0.35) | ADRA1AADRA1BADRA1DDRD2 | |
| SCHEMBL6194542 | 0.82 | MEN1 (0.43) | ADRA1B | |
| SCHEMBL6194124 | 0.82 | CHRM4 (0.38) | ADRA1ADRD2 | |
| SCHEMBL6193318 | 0.81 | HTR1A (0.38) | ADRA1ADRD2 | |
| SCHEMBL6191394 | 0.81 | ADRA1D (0.40) | ADRA1AADRA1BADRA1DDRD2 | |
| SCHEMBL6194271 | 0.80 | DRD2 (0.39) | ADRA1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | claimed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | claimed |
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | ADRA1A 36/4885ADRA1B 47/4885ADRA1D 17/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | ADRA1A 27/4885ADRA1B 36/4885ADRA1D 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.